Michael Havert, PhD FDA

Michael Havert has been a full time CMC Reviewer in the Office of Cell, Tissue, and Gene Therapies (OCTGT) since 2004, where he is responsible for reviewing gene therapy investigational new drug applications and related submissions. His work in OCTGT has involved application of NEPA regulations in CBER and drafting guidance related to environmental assessment. Dr. Havert received a Ph.D. from the University of Wisconsin and has specialized training in virology at Johns Hopkins University and the National Institutes of Health.